SYSTEMIC SCLEROSIS

This early-phase trial is testing a new treatment called KYV-101 for people with systemic sclerosis, a disease where the immune system attacks the body, causing skin and organ damage. The therapy uses a patient's own modified immune cells to target and destroy certain B cells tha…

This study tests a new treatment using donor immune cells (CAR T-cells) that are engineered to target and destroy faulty immune cells causing lupus or scleroderma. The goal is to control the disease in patients who have not responded to standard therapies. The trial involves 18 a…

This early-stage trial is testing a new treatment for people with severe lupus or scleroderma that hasn't responded to standard therapies. The treatment involves taking a patient's own immune cells, engineering them to target and destroy disease-causing immune cells, and then giv…

This phase 4 trial tests whether baricitinib, an oral drug, can improve skin thickening in people with systemic sclerosis, a rare autoimmune disease. 60 participants will receive either baricitinib or standard treatment (cyclophosphamide plus prednisone) for 24 weeks, then all sw…

This study tests a new drug called CM-101 for people with systemic sclerosis, a disease that causes skin hardening and organ damage. About 45 adults will receive either the drug or a placebo to check safety and how well the body tolerates it. The goal is to see if CM-101 can redu…

This early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy faulty immune cells. The goal is to see if it is safe and can help control active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrom…

This study tests a drug called anifrolumab against a placebo in 314 adults with systemic sclerosis (scleroderma), a disease that causes skin and organ scarring. Participants receive injections and are monitored for improvements in skin tightness, lung function, and daily activiti…

This early-phase study tests KITE-363, a personalized therapy where a patient's own immune cells are modified to target and attack faulty B cells that drive autoimmune diseases like lupus and scleroderma. About 52 adults with severe, treatment-resistant forms of these conditions …

This study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardness over 26 weeks. Researchers will also check …

This study looks at whether the Shingrix vaccine is safe and effective for preventing shingles in people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus. About 2,000 patients will receive the vaccine or a placebo, and researchers will monitor for disease fl…

This study tests whether fecal microbiota transplantation (FMT) — giving healthy donor stool in capsule form — can safely reduce chronic diarrhea in people with systemic sclerosis, an autoimmune disease. Twenty participants will receive either FMT or a placebo and report their sy…

This study tests an 8-week online group program designed to help people with scleroderma improve their thinking skills and overall well-being. Researchers will compare participants who take the program right away to those on a waitlist. The goal is to see if the program boosts me…

This study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…

This study looks at CT scans from 1000 people with systemic sclerosis (a disease that can cause lung scarring) to see if computer analysis can predict who will get worse. Researchers will check if certain patterns in the lungs, airways, and blood vessels can forecast breathing de…

This study planned to collect extra blood and urine samples from scleroderma patients during their regular check-ups to find biological markers that could predict if their disease would get worse over the next 10 years. The goal was to improve treatment decisions and identify the…